Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of pediatric bosentan in Japanese children with pulmonary arterial hypertension
jRCT2080222109Phase 3
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bosentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Long-term efficacy, Long-term safety and 1 more.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2080222109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222109.